Embecta Corporation (EMBC)
NASDAQ:EMBC
Want to see EMBC full AI Analyst Report?
EMBC Stock Chart & Stats
$9.78
$0.16(0.83%)
At close: 4:00 PM EST
$9.78
$0.16(0.83%)
Day’s Range― - ―
52-Week Range$2.77 - $15.55
Previous CloseN/A
Volume119.84K
Average Volume (3M)2.72M
Market Cap
$196.97M
Enterprise Value$1.37B
Total Cash (Recent Filing)$184.90M
Total Debt (Recent Filing)$1.36B
Price to Earnings (P/E)―
Beta0.70
Next Earnings
Aug 07, 2026EPS Estimate
0.27Next Dividend Ex-DateN/A
Dividend Yield5.03%
Share Statistics
EPS (TTM)1.91
Shares Outstanding59,327,680
10 Day Avg. Volume3,300,754
30 Day Avg. Volume2,718,237
Financial Highlights & Ratios
PEG Ratio0.42
Price to Book (P/B)-1.26
Price to Sales (P/S)0.76
P/FCF Ratio4.51
Enterprise Value/Market Cap6.95
Enterprise Value/Revenue1.31
Enterprise Value/Gross Profit2.10
Enterprise Value/Ebitda4.11
Forecast
1Y Price Target
$4.00Price Target Upside-59.10% Downside
Rating ConsensusModerate Sell
Number of Analyst Covering3
EPS Forecast (FY)1.57
Revenue Forecast (FY)$1.02B
Bulls Say, Bears Say
Bulls Say
Acquisition And Product ExpansionAcquisition broadens the product portfolio by adding the Aidaptus auto-injector platform and strengthens B2B relationships with generic pharmaceutical partners, supporting new device-led offerings.
Co‑packaging PartnershipsCo-packaging agreements with generic GLP-1 manufacturers could create a meaningful multi-country revenue opportunity for pen needles and related delivery systems.
Operational And Financial DisciplineContinued debt reduction and disciplined cost controls have improved leverage and increase financial flexibility to support growth initiatives or absorb operational shocks.
Bears Say
Increased Leverage And Interest BurdenAcquisition-related increase in leverage could raise annual interest payments and place near-term pressure on cash flow available for operations and growth.
U.S. Pricing PressurePersistent pricing pressure in the U.S. market driven by competition and customer mix could reduce revenue and limit upside to guidance.
Embecta Corporation News
EMBC FAQ
What was Embecta Corporation’s price range in the past 12 months?
Embecta Corporation lowest stock price was $2.77 and its highest was $15.55 in the past 12 months.
What is Embecta Corporation’s market cap?
Embecta Corporation’s market cap is $196.97M.
When is Embecta Corporation’s upcoming earnings report date?
Embecta Corporation’s upcoming earnings report date is Aug 07, 2026 which is in 74 days.
How were Embecta Corporation’s earnings last quarter?
Embecta Corporation released its earnings results on May 05, 2026. The company reported $0.27 earnings per share for the quarter, missing the consensus estimate of $0.417 by -$0.147.
Is Embecta Corporation overvalued?
According to Wall Street analysts Embecta Corporation’s price is currently Overvalued.
Does Embecta Corporation pay dividends?
Embecta Corporation pays a Quarterly dividend of $0.15 which represents an annual dividend yield of 5.03%. See more information on Embecta Corporation dividends here
What is Embecta Corporation’s EPS estimate?
Embecta Corporation’s EPS estimate is 0.27.
How many shares outstanding does Embecta Corporation have?
Embecta Corporation has 59,327,680 shares outstanding.
What happened to Embecta Corporation’s price movement after its last earnings report?
Embecta Corporation reported an EPS of $0.27 in its last earnings report, missing expectations of $0.417. Following the earnings report the stock price went down -57.838%.
Which hedge fund is a major shareholder of Embecta Corporation?
Currently, no hedge funds are holding shares in EMBC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Embecta Corporation Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Sell
Average Price Target:
$4.00 (-59.10% Downside)
$4.00 (-59.10% Downside)
Blogger Sentiment
Neutral
EMBC Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 825.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 3.7%
Last 30 Days ▲ 2.8%
Last 30 Days ▲ 2.8%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-66.73%
12-Months-Change
Fundamentals
Return on Equity
-17.49%
Trailing 12-Months
Asset Growth
-8.11%
Trailing 12-Months
Company Description
Embecta Corporation
Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety devices, as well as digital applications to assist people with managing their diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is based in Parsippany, New Jersey. Embecta Corp.(NasdaqGS:EMBC) operates independently of Becton, Dickinson and Company as of April 1, 2022.
EMBC Company Deck
EMBC Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Negative
The call presents meaningful strategic progress (Owen Mumford acquisition, GLP‑1 B2B traction, brand transition progress, debt repayment and a share buyback authorization) but was dominated by substantial near‑term operational and financial setbacks: large revenue declines (especially in the U.S. and pen needles), sharp margin and EPS guide cuts, a GAAP net loss in the quarter, and material reductions in free cash flow guidance. Management has initiated cost/organization reviews and highlighted actions underway, but the magnitude and persistence of the U.S. share loss and market volume softness create significant short‑term headwinds.View all EMBC earnings summariesEMBC Stock 12 Month Forecast
Average Price Target
$4.00
▼(-59.10% Downside)
Technical Analysis
―
Pacira Pharmaceuticals
―
SIGA Technologies
―
Collegium Pharmaceutical
―
Organogenesis Holdings
―
Ownership Overview
3.19% Insiders
24.51% Mutual Funds
29.65% Other Institutional Investors
18.77% Public Companies and
Individual Investors